Simcere Pharmaceutical Group Gestione

Gestione criteri di controllo 1/4

Simcere Pharmaceutical Group Il CEO è Jinsheng Ren, nominato in Mar1995, e ha un mandato di 29.67 anni. la retribuzione annua totale è CN¥ 7.43M, composta da 67.6% di stipendio e 32.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 4.97% delle azioni della società, per un valore di HK$ 815.40M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.8 anni e 5 anni.

Informazioni chiave

Jinsheng Ren

Amministratore delegato

CN¥7.4m

Compenso totale

Percentuale dello stipendio del CEO	67.6%
Mandato del CEO	29.7yrs
Proprietà del CEO	5.0%
Durata media del management	1.8yrs
Durata media del Consiglio di amministrazione	5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Simcere Pharmaceutical Group Limited's (HKG:2096) P/S Still Appears To Be Reasonable

Nov 21

Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing

Jul 29

Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems

May 01

Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market

Dec 29

Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates

Aug 28

Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?

Jun 03

Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically

Apr 06

Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)

Jan 10

With EPS Growth And More, Simcere Pharmaceutical Group (HKG:2096) Makes An Interesting Case

Aug 16

Simcere Pharmaceutical Group (HKG:2096) Has Announced A Dividend Of HK$0.18

Jun 27

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jinsheng Ren rispetto agli utili di Simcere Pharmaceutical Group?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-CN¥1b
Mar 31 2024	n/a	n/a	-CN¥194m
Dec 31 2023	CN¥7m	CN¥5m	CN¥715m
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥3b
Mar 31 2023	n/a	n/a	CN¥2b
Dec 31 2022	CN¥3m	CN¥2m	CN¥931m
Sep 30 2022	n/a	n/a	CN¥972m
Jun 30 2022	n/a	n/a	CN¥1b
Mar 31 2022	n/a	n/a	CN¥1b
Dec 31 2021	CN¥2m	CN¥2m	CN¥2b
Sep 30 2021	n/a	n/a	CN¥1b
Jun 30 2021	n/a	n/a	CN¥1b
Mar 31 2021	n/a	n/a	CN¥856m
Dec 31 2020	CN¥2m	CN¥1m	CN¥670m
Sep 30 2020	n/a	n/a	CN¥699m
Jun 30 2020	n/a	n/a	CN¥728m
Mar 31 2020	n/a	n/a	CN¥866m
Dec 31 2019	CN¥2m	CN¥1m	CN¥1b

Compensazione vs Mercato: La retribuzione totale di Jinsheng ($USD 1.03M ) è superiore alla media delle aziende di dimensioni simili nel mercato Hong Kong ($USD 487.65K ).

Compensazione vs guadagni: La retribuzione di Jinsheng è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Jinsheng Ren (62 yo)

29.7yrs

Mandato

CN¥7,426,000

Compensazione

Mr. Jinsheng Ren founded Simcere Pharmaceutical Group Limited in March 1995 and its Chairman since 2023 and serves as its Director and also serves as its Chief Executive Officer since November 19, 2019 an...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jinsheng Ren	Co-Founder	29.7yrs	CN¥7.43m	4.97% HK$ 815.4m
Yushan Wan	CFO, Joint Company Secretary & Executive Director	5yrs	CN¥9.36m	0.049% HK$ 8.1m
Renhong Tang	Executive Director	1.8yrs	CN¥14.53m	0.062% HK$ 10.2m
Xi Wang	VP & Executive Director	1.8yrs	CN¥1.33m	Nessun dato
Gaobo Zhou	Chief Investment Officer	1.8yrs	Nessun dato	Nessun dato
Quanfu Feng	Vice President of Marketing	no data	Nessun dato	Nessun dato
Tamas Oravecz	Senior VP & Chief Scientific Officer of Simcere Zaiming	2.2yrs	Nessun dato	Nessun dato
Aik Han Goh	Senior VP & Chief Medical Officer	less than a year	Nessun dato	Nessun dato
Wang John	Senior Vice President	less than a year	Nessun dato	Nessun dato
Yongyu Wang	Senior VP & Chief Medical Officer of Simcere Zaiming	less than a year	Nessun dato	Nessun dato
Ling Wong Wai	Joint Company Secretary	less than a year	Nessun dato	Nessun dato

1.8yrs

Durata media

49yo

Età media

Gestione esperta: Il team dirigenziale di 2096 non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jinsheng Ren	Co-Founder	9yrs	CN¥7.43m	4.97% HK$ 815.4m
Yushan Wan	CFO, Joint Company Secretary & Executive Director	5yrs	CN¥9.36m	0.049% HK$ 8.1m
Renhong Tang	Executive Director	5yrs	CN¥14.53m	0.062% HK$ 10.2m
Xi Wang	VP & Executive Director	1.8yrs	CN¥1.33m	Nessun dato
Jianguo Wang	Independent Non-Executive Director	5yrs	CN¥360.00k	Nessun dato
Xinhua Wang	Independent Non-Executive Director	5yrs	CN¥360.00k	Nessun dato
Ruilin Song	Independent Non-Executive Director	5yrs	CN¥360.00k	Nessun dato
Ka Woon Sung	Independent Non-Executive Director	1.8yrs	CN¥360.00k	Nessun dato

5.0yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 2096 sono considerati esperti (durata media dell'incarico 5 anni).

Simcere Pharmaceutical Group Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Co-Founder recently sold HK$1.2m worth of stock

Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 14, 2024

Co-Founder recently bought HK$1.2m worth of stock

Co-Founder recently sold HK$710k worth of stock

Co-Founder recently sold HK$2.3m worth of stock

Co-Founder recently bought HK$1.5m worth of stock

Recent updates

Simcere Pharmaceutical Group Limited's (HKG:2096) P/S Still Appears To Be Reasonable

Simcere Pharmaceuticals Group Ltd. Announces That A New Clinical Study with Major Clinical Findings Regarding Sanbexin (Edaravone and Dexborneol Concentrated Solution for Injection) Has Been Published At the 16th World Stroke Conference

First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023)

Simcere Pharmaceuticals Group Ltd. Announces Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the United States Food and Drug Administration

First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023)

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024

Now 22% overvalued

Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing

Simcere Pharmaceutical Group Limited Announces New Drug Application of Quviviq (Daridorexant Hydrochloride Tablets) Has Been Accepted by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Regular Approval of Xiannuoxin, an Anti-Sars-Cov-2 Innovative Drug

Co-Founder recently sold HK$1.2m worth of stock

Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback for 260,976,161 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2024.

Upcoming dividend of CN¥0.16 per share

Simcere Pharmaceutical Group Limited Announces Phase III Clinical Study of Daridorexant Hydrochloride Tablets in the Treatment of Insomia Patients in China

Simcere Pharmaceutical Group Limited and Idorsia Pharmaceuticals Ltd. Announces the Hypnotics Daridorexant Hydrochloride Tablets Obtains the Certificate of Drug/ Product Registration Issued by the Pharmacy and Poisons Board of Hong Kong

Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 14%

Dividend of CN¥0.16 announced

Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 14, 2024

Consensus EPS estimates fall by 37%

Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500

Simcere Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023

Consensus EPS estimates fall by 35%

Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0501 Tablets

Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market

Simcere Pharmaceutical Group Limited Announces Localization Application of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug for SIM0501 (An Usp1 Small-Molecule Inhibitor) Issued by U.S. Food and Drug Administration

Simcere Pharmaceutical Group Limited and Neurodawn Pharmaceutical Co., Ltd. Obtains Clinical Trial Approval Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Approval of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for New Indication of Sim0237 for Injection (Anti-Pd-L1/IL-15 Bispecific Antibody) Issued by the National Medical Products Administration

Co-Founder recently bought HK$1.2m worth of stock

Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates

Consensus revenue estimates fall by 22%

First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022)

Simcere Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 21, 2023

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

Co-Founder recently sold HK$710k worth of stock

New minor risk - Insider selling

Co-Founder recently sold HK$2.3m worth of stock

Simcere Pharmaceutical Group Limited Approves Final Cash Dividend for the Year Ended December 31, 2022, Payable on 12 July 2023

Co-Founder recently bought HK$1.5m worth of stock

Upcoming dividend of CN¥0.16 per share at 2.3% yield

Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?

Co-Founder recently sold HK$3.1m worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 15%

Consensus revenue estimates fall by 13%

Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically

Now 23% undervalued

Simcere Pharmaceutical Group Limited Announces Conditional Approval for Marketing in China of Anti-Sars-Cov-2 Innovative Drug Xiannuoxin Tm Granted by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Appointment Wang Xi as an Executive Director and the Appointment of Sung Ka Woon as an Independent Non-Executive Director

Investor sentiment deteriorated over the past week

Simcere Pharmaceutical Group Limited Announces Acceptance of New Drug Application of Anti-SARS-CoV-2 Innovative Drug Xiannuoxin (Simnotrelvir Tablets/Ritonavir Tablets (Co-Packaged)) by the National Medical Products Administration

Now 24% undervalued

Co-Founder recently bought HK$7.9m worth of stock

Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)

Simcere Pharmaceutical Group Limited Appoints Mr. Tang Renhong as the Chairman of the Board of Directors and Chief Executive Officer of Simcere Zaiming Pharmaceutical Co., Ltd., with Effect from January 1, 2023

Simcere Pharmaceutical Group Limited Announces - the Clinical Trial Approval for SIM0348 Injection (Humanized TIGIT/PVRIG Bispecific Antibody) Issued by the National Medical Products Administration

Now 20% undervalued